SCHEMBL7043941

SCHEMBL7043941

Cc1ncccc1-c1ccncc1-c1ccc(S(C)(=O)=O)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.44
ALOX5AP P20292 8/20 0.43
FEN1 P39748 8/20 0.43
RPS6KA3 P51812 2/20 0.43
PTGS1 P23219 1/20 0.42
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
GPBAR1 Q8TDU6 1/20 0.40
GRM4 Q14833 1/20 0.39
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
SLC22A12 Q96S37 1/20 0.39
F10 P00742 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6735867 0.85 RPS6KA3 (0.44) PTGS2FEN1RPS6KA3PTGS1GPBAR1
SCHEMBL7041056 0.85 PTGS2 (0.52) PTGS2RPS6KA3PTGS1SLC22A12
SCHEMBL6741149 0.84 PTGS2 (0.43) PTGS2ALOX5APFEN1PTGS1GPBAR1
SCHEMBL7045230 0.84 RPS6KA3 (0.57) PTGS2ALOX5APFEN1RPS6KA3SLC22A12
SCHEMBL7546134 0.84 RPS6KA3 (0.61) PTGS2RPS6KA3PTGS1PIK3CDPIK3CA
SCHEMBL7170268 0.84 PTGS2 (0.50) PTGS2ALOX5APFEN1RPS6KA3PIK3CD
SCHEMBL7111676 0.83 PTGS2 (0.49) PTGS2ALOX5APFEN1RPS6KA3PIK3CD
SCHEMBL7116024 0.83 RPS6KA3 (0.64) PTGS2RPS6KA3SLC22A12
SCHEMBL7108675 0.82 PTGS2 (0.49) PTGS2RPS6KA3PTGS1PIK3CDPIK3CA
SCHEMBL7114909 0.82 PTGS2 (0.49) PTGS2RPS6KA3PTGS1PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885ALOX5AP 454/4885FEN1 1649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.